Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

Table 1 Baseline patient and tumor characteristics

Characteristics	All (n = 32)
Age (yr) (median)	72 (range 44-89)
Gender: Male/female	28/4
Etiology
Alcohol/HBV/HCV/NASH	14/4/12/2
Child-Pugh classification A/B	23/9
Previous treatment (y/n)	18/14
Tumor number	39
Tumor size (mm) (median)	21 (range 8-50)
Tumor location
Peripheral/central	26/13
DCBead (100-300 μm, mL) (median)	0.6 (range 0.2-1.5)
Vascular lake (y/n)	7/32 (22%)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Non-alcoholic steatohepatitis.

Table 2 Adverse events in 32 patients after 39 transarterial chemoembolization with drug-eluting beads procedures

Adverse event	Grade 1-24	Grade 3-44
Fever ≥ 37.5 °C	19 (48.7)	0
Abdominal pain	3 (7.7)	0
Nausea and/or vomiting	0	0
Catheterization-site bleeding1	0	0
Transient renal insufficiency	0	0
Groin hematoma2	0	0
Liver decompensation3	0	0
Hepatic abscess	0	0
Intratumor bleeding	0	0

Data are given as n (%).

¹Controlled with local compressive medication;

²Both self-limiting and resolved within 2 wk of the procedure;

³Mild ascites treated successfully with oral aldosterone antagonists;

⁴According to the CTCAE, version 4.0 (v4.03). CTCAE: Common Terminology Criteria for Adverse Events.